The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
Current Oncology · 09.06.2023 · 30 (6) · 5574-5592
DOI: 10.3390/curroncol30060421 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 09.06.2023. Verfasst von Letizia Todeschini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Surgery, University of Verona, 37134 Verona, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Transplantation. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Liver transplantation is a treatment option for nonresectable patients with early-stage HCC, with more significant advantages when Milan criteria are fulfilled. An immunosuppressive regimen is required to reduce the risk of graft rejection after transplantation, and CNIs represent the drugs of choice in this setting. However, their inhibitory effect on T-cell activity accounts for a higher risk of tumour regrowth. mTOR inhibitors (mTORi) have been introduced as an alternative immunosuppressive approach to conventional CNI-based regimens to address both immunosuppression and cancer control. The PI3K-AKT-mTOR signalling pathway regulates protein translation, cell growth, and metabolism, and the pathway is frequently deregulated in human tumours. Several studies have suggested the role of mTORi in reducing HCC progression after LT, accounting for a lower recurrence rate. Furthermore, mTOR immunosuppression controls the renal damage associated with CNI exposure. Conversion to mTOR inhibitors is associated with stabilizing and recovering renal dysfunction, suggesting an essential renoprotective effect. Limitations in this therapeutic approach are related to their negative impact on lipid and glucose metabolism as well as on proteinuria development and wound healing. This review aims to summarize the roles of mTORi in managing patients with HCC undergoing LT. Strategies to overcome common adverse effects are also proposed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Surgery, University of Verona, 37134 Verona, Italy.
- Department of Surgery, University of Illinois Chicago, Chicago, IL 60607, USA.
- General Surgery and Liver Transplantation Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
ORCID-Profile: Alessandro Martinino, Francesco Giovinazzo
Zitieren
APA
Todeschini, L., Cristin, L., Martinino, A., Mattia, A., Agnes, S., & Giovinazzo, F. (2023). The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma. Current Oncology, 30(6), 5574-5592. https://doi.org/10.3390/curroncol30060421
Vancouver
Todeschini L, Cristin L, Martinino A, Mattia A, Agnes S, Giovinazzo F. The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma. Current Oncology. 2023;30(6):5574-5592. doi:10.3390/curroncol30060421
BibTeX
@article{Todeschini2023,
author = {Todeschini, Letizia and Cristin, Luca and Martinino, Alessandro and Mattia, Amelia and Agnes, Salvatore and Giovinazzo, Francesco},
title = {The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {6},
pages = {5574--5592},
doi = {10.3390/curroncol30060421}
}
EUVIMED